Markets

Moderna's Data From Its Current Phase 1/2 Trial Of mRNA-2808 Selected For Oral Presentation At 68th American Society Of Hematology Annual Meeting

Nov 4, 2026 · 10:03 AM ET· updated 2h ago

Moderna, Inc. (NASDAQ:MRNA) today announced that initial clinical data from its ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of Hematology (ASH) Annual

Why It Matters

Moderna's new medicine got picked to be shown at a big doctor meeting. This means doctors think the early results are interesting enough to talk about.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MRNA246.38

+17.94 (+7.85%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.